Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Phase III Clinical Trial to Evaluate the Safety and Efficacy of Injectable Tyroserleutide to Treat Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Jul 2018
Price :
$35
*
At a glance
- Drugs Tyroserleutide (Primary) ; Fluorouracil; Mitomycin
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shenzhen Kangzhe Pharmaceutical
- 12 Dec 2011 New trial record